Barely Significant
← all excerpts

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.

JCO Glob Oncol · 2021 · PMC8457874 · PMID 34086481

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendP = .05actually significant
Interestingly, patients with high RS (26-30) showed a trend toward a higher major response rate ( P = .05).

also in 50,778 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.